Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Litorina V and the JOHBECO Group in connection with the acquisition of Arvo Kokkonen Oy
Mandate

Vinge advises Litorina V and the JOHBECO Group in connection with the acquisition of Arvo Kokkonen Oy

September 30, 2019 M&A

Arvo Kokkonen Oy is a leading Finnish distributor of fresh produce with a focus on fish and shellfish.

The Swedish fresh produce group JOHBECO, consisting of, among others, Johan i Hallen and Bergfalk & Co, has strengthened its position in Finland through the acquisition of the Finnish fish and shellfish specialist Arvo Kokkonen Oy. Thanks to the partnership, Arvo Kokkonen can now offer its customers in Finland a full range of high quality fresh produce, including meat and charcuterie.

Vinge’s team consisted of partners Jonas Johansson and Matthias Pannier together with, among others, associates Carl Sander and Vilhelm Rondahl (M&A). Partner Louise Brorsson Salomon and associate Lionardo Ojeda advised on financing.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024